Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) shares were down 2% during trading on Thursday . The company traded as low as $0.92 and last traded at $1.00. Approximately 117,251 shares were traded during trading, a decline of 10% from the average daily volume of 130,474 shares. The stock had previously closed at $0.98.

The stock has a market capitalization of $91.10, a price-to-earnings ratio of -2.68 and a beta of 0.69.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Wednesday, November 15th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%.

A hedge fund recently bought a new stake in Matinas BioPharma stock. Yellowstone Partners LLC bought a new position in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 143,914 shares of the company’s stock, valued at approximately $190,000. Yellowstone Partners LLC owned 0.16% of Matinas BioPharma as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at

About Matinas BioPharma

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.